Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and...
One of my followers asked (and this has never happened before) for me to comment on LABU. I was touched by the request and so I have responded, and this after having a website which I shut down with 10,000 hits a month never once did anyone ask me to comment on a stock. My strength has always been analysis and dissection so I am happy to oblige. LABU isn't...
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 -...
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Cala looks to have established a double bottom. New strong uptrend suggests it has potentially capitulated from the selloff making these levels very attractive for any investors who are sidelined and looking for a good technical/ fundamental trade in biotech. Cala looks to be...
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
It sounds like the trade war between USA and China is about to get resolved. IF it does I expect a move higher for the markets. With LABU sitting on lower support, it should be a short term low risk BUY.
Target 10,000. I can't believe I said that... but there is just too much confluence to ignore this possibility. However, a breakdown from this wedge will likely eliminate this play. Either we hit it fast in 2019, or this long is off the table. Let me know your thoughts.
The biotech sector is really interesting when you dive down into the symmetry of the last few cycles. Early 2000s-2008 and 2016-2018 are mini rallies within the bigger wedge. If this pattern is to continues, you can look for entry around the end of 2020 when we bump up against the larger support line (around $3600), and expect to hit the resistance of the larger...
XBI getting ready for a move after some super healthy consolidation, bulls need to see a break of the 101.05/101.06 double top and a break of RSI resistance for room to the upside. Earnings from some larger names will like help XBI to pick a direction soon. LABD and LABU will be on my radar this week. I will be much more likely to play a break if overall market...
LABU setting up for another run higher? Indicators would suggest it. Buy the dip...........
Maybe time to jump back in with LABU. The pharma 3X is looking ripe to move higher.
Looking to go long with LABU. Looking for a retest of the lower trend line. Previous times it bounced and retrested the break. BUY limit order at $65.50